Monitor the HSR clearance and any updates on development timeline for civorebrutinib. The recent executive departure (May 21) could indicate management transition; watch for further changes or clarity on leadership. The deal adds pipeline value but increases near-term cash burn.
Price Chart
Executive Summary
Travere Therapeutics entered into a license and collaboration agreement with EverestMedicines for exclusive rights to develop and commercialize civorebrutinib (BTK inhibitor) outside China and Southeast Asia. Travere will pay $112.5M upfront with up to ~$1.03B in milestones and tiered royalties. The deal expands Travere's pipeline in immune-mediated kidney diseases but carries development and cash burn risks. A recent executive departure (8-K filed May 21) adds uncertainty around management continuity.
Key Financial Metrics
Key Facts
- Exclusive license for civorebrutinib (EVER001), a BTK inhibitor, for all therapeutic uses outside China and parts of Southeast Asia
- Upfront payment of $112.5 million to Everest
- Potential milestones up to approximately $1.03 billion across up to five indications
- Tiered royalties from high single-digit to double-digit percentages on net sales
- Travere responsible for development and commercialization in the Territory; cost-sharing on global trials
- Agreement subject to HSR waiting period and other customary conditions
- Prior 8-K (May 21, 2026) disclosed an executive departure and equity plan amendment
Financial Impact
Upfront payment of $112.5 million, plus up to $1.03 billion in contingent milestones and tiered royalties
Risk Factors
- Cash burn from $112.5M upfront and ongoing development costs
- Clinical and regulatory risks for civorebrutinib (still in development)
- Potential management disruption from recent executive departure
- Competition in BTK inhibitor space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-252474 |
| Document: 0001193125-26-252474-index-headers.html | 0001193125-26-252474 |
| Document: 0001193125-26-252474-index.html | 0001193125-26-252474 |
| Document: 0001193125-26-252474.txt | 0001193125-26-252474 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 9, 2026 12w ago | 8-K | $56.59 $61.32 | ▲ +8.36% | ▲ +5.93% | $56.93 (+0.60%) |
Jun 16, 2026 15w ago | Insider Cluster | $54.14 $55.28 | ▲ +2.11% | ▲ +0.79% | $56.93 (+5.15%) |
Jun 16, 2026 15w ago | 8-K | $54.14 $55.28 | ▲ +2.11% | ▲ +0.79% | $56.93 (+5.15%) |
Jun 12, 2026 16w ago | 144 | $52.04 $56.59 | ▲ +8.74% | ▲ +6.96% | $56.93 (+9.40%) |
Jun 2, 2026 17w ago | 8-K | $42.96 $56.34 | ▲ +31.15% | ▲ +32.71% | $56.93 (+32.52%) |
May 15, 2026 20w ago | 144 | $42.59 $53.80 | ▲ +26.32% | ▲ +24.20% | $56.93 (+33.67%) |
May 5, 2026 21w ago | 144 | $44.76 $45.20 | ▲ +0.98% | ▼ −1.80% | $56.93 (+27.19%) |
May 4, 2026 21w ago | 144 | $44.80 $42.96 | ▼ −4.11% | ▼ −9.06% | $56.93 (+27.08%) |
May 1, 2026 22w ago | Insider Cluster | $44.12 $45.04 | ▼ −2.09% | ▲ +3.20% | $56.93 (−29.03%) |
Apr 15, 2026 24w ago | 144 | $40.95 $42.84 | ▲ +4.62% | ▼ −1.43% | $56.93 (+39.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access